Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
1.
Ann Endocrinol (Paris) ; 84(4): 430-439, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37086950

ABSTRACT

PURPOSE: To identify initial features associated with significant recovery in patients with Graves' disease dysthyroid optic neuropathy (DON) treated according to EUGOGO guidelines by intravenous glucocorticoids (ivGC) and decompression surgery in first and second-line, respectively. PATIENTS AND METHODS: Consecutive patients referred to our expert multidisciplinary consultation over a 6-year period underwent systematic exploration: endocrine assessment, ophthalmic examination and radiological exploration. Visual recovery, based on best-corrected visual acuity (BCVA) and visual field (VF), were evaluated at baseline, 1week and 6months. Baseline parameters were then tested for prognostic value on univariate and multivariate analyses. RESULTS: Thirty-eight patients (69 eyes) with DON were included. Significant recovery at 6months was found in 48/69 eyes (70%), partial recovery in 18/69 (26%), and no recovery in 3/69 (4%). Fifty-one eyes (28 patients) required surgical decompression after ivGC. These patients showed more severe presentation at diagnosis, had received significantly less GC for Graves' orbitopathy before onset of DON, and showed greater fat prolapse on CT scans compared to non-operated patients. On multivariate analysis, male gender (P=0.001), cumulative GC dose>1g before DON diagnosis (P=0.048) and initial BCVA≤0.3 (P=0.004) were significantly associated with better outcomes, whereas Clinical Activity Score>5 (P=0.013) was associated with a poorer outcome. CONCLUSION: This study confirms a generally favorable 6-month recovery rate in DON treated according to EUGOGO guidelines and provides new information on baseline predictors of poor evolution. These results may help the respective indications for medical and surgical treatment to be more effectively combined in the future.


Subject(s)
Graves Ophthalmopathy , Optic Nerve Diseases , Humans , Male , Graves Ophthalmopathy/complications , Graves Ophthalmopathy/surgery , Graves Ophthalmopathy/diagnosis , Optic Nerve Diseases/diagnosis , Optic Nerve Diseases/etiology , Optic Nerve Diseases/surgery , Prognosis , Visual Acuity , Decompression, Surgical/methods , Glucocorticoids/therapeutic use , Retrospective Studies
2.
Thyroid ; 29(5): 743-747, 2019 05.
Article in English | MEDLINE | ID: mdl-30973063

ABSTRACT

Background: Thyroid-stimulating hormone (TSH) receptor (TSHR) antibodies (TRAb) can be present in chronic autoimmune thyroiditis. Transplacental TRAb transfer can lead to fetal thyroid dysfunction and serious complications. Patient Findings: We report the case of a woman with autoimmune hypothyroidism and extremely high TRAb levels, with blocking and stimulating activities (biological activities characterized with Chinese hamster ovary cells expressing TSHR). At week 22 of her first pregnancy, sonography detected fetal growth retardation and cardiac abnormalities (extreme tachycardia, right ventricular dilatation, pericardial effusion). The mother's TRAb level, assayed later, was 4030 IU/L (n < 10). Delivered via caesarean section gestational week 30, the newborn girl had several malformations, signs of malnutrition, goiter and hyperthyroidism associated with elevated TRAb (1200 IU/L). The newborn died 26 days after delivery. Faced with persistently high TRAb levels and a desire to become pregnant again, the woman was treated with three consecutive 740-MBq activities of iodine-131, which resulted in a decrease in TRAb to 640 IU/L. The patient had two subsequent pregnancies 16 and 72 months after the radioiodine administration. During the close follow-ups, fetal development was normal, and initial TRAb levels during the two pregnancies were 680 and 260 IU/L, respectively, which initially decreased but then increased in late pregnancy. In both cases, labor was induced at 34 weeks. The newborns, mildly hyperthyroid at birth, required carbimazole treatment at days 5 and 2, respectively. The mild hyperthyroidism despite high TRAb levels was likely due to the concomitant presence of stimulating and blocking TRAb. The two girls, now aged 12 and 8 years, are in good health. The mother has no detectable thyroid gland tissue and is euthyroid on levothyroxine (175 µg/d). Her TRAb level gradually decreased to 136 IU/L. Summary and Conclusions: This remarkable case illustrates the severe consequences of untreated fetal hyperthyroidism and the need to assay and follow-up TRAb levels in women of reproductive age with autoimmune thyroiditis.


Subject(s)
Autoantibodies/blood , Hashimoto Disease/immunology , Pregnancy Complications/immunology , Receptors, Thyrotropin/immunology , Thyroiditis, Autoimmune/immunology , Adult , Child , Chronic Disease , Female , Hashimoto Disease/complications , Humans , Infant, Newborn , Pregnancy , Thyroiditis, Autoimmune/complications
3.
Eur Thyroid J ; 7(4): 165-166, 2018 Aug.
Article in English | MEDLINE | ID: mdl-30283734
4.
Ann Endocrinol (Paris) ; 79(6): 618-635, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30193753

ABSTRACT

Treatment strategy in Graves' disease firstly requires recovery of euthyroid status by antithyroid therapy. Treatment modalities, precautions, advantages and side-effects are to be discussed with the patient. No particular treatment modality has demonstrated superiority. Pregnancy or pregnancy project affects choice of treatment and monitoring. Graves' orbitopathy is liable to be aggravated by iodine-131 treatment and requires pre-treatment assessment. Iodine-131 treatment aims at achieving hypothyroidism. Thyroid surgery for Graves' disease should preferably be performed by an expert team. In case of recurrence of hyperthyroidism, the various treatment options should be discussed with the patient. Empiric treatment of thyroid dermopathy uses local corticosteroids in occlusive dressing.


Subject(s)
Graves Disease/therapy , Adult , Age of Onset , Antithyroid Agents/therapeutic use , Female , Graves Disease/epidemiology , Humans , Iodine Radioisotopes/therapeutic use , Pregnancy , Pregnancy Complications/therapy , Radiotherapy Dosage/standards , Thyroidectomy/methods , Thyroidectomy/standards
5.
Cancer Epidemiol ; 52: 142-147, 2018 02.
Article in English | MEDLINE | ID: mdl-29324353

ABSTRACT

BACKGROUND: The Chernobyl nuclear power plant accident occurred in Ukraine on April 26th 1986. In France, the radioactive fallout and thyroid radiation doses were much lower than in highly contaminated areas. However, a number of risk projections have suggested that a small excess in differentiated thyroid cancer (DTC) might occur in eastern France due to this low-level fallout. In order to investigate this potential impact, a case-control study on DTC risk factors was started in 2005, focusing on cases who were less than 15 years old at the time of the Chernobyl accident. Here, we aim to evaluate the relationship between some specific reports of potentially contaminated food between April and June 1986 - in particular fresh dairy products and leafy vegetables - and DTC risk. METHODS: After excluding subjects who were not born before the Chernobyl accident, the study included 747 cases of DTC matched with 815 controls. Odds ratios were calculated using conditional logistic regression models and were reported for all participants, for women only, for papillary cancer only, and excluding microcarcinomas. RESULTS: The DTC risk was slightly higher for participants who had consumed locally produced leafy vegetables. However, this association was not stronger in the more contaminated areas than in the others. Conversely, the reported consumption of fresh dairy products was not statistically associated with DTC risk. CONCLUSION: Because the increase in DTC risk associated with a higher consumption of locally produced vegetables was not more important in the most contaminated areas, our study lacked power to provide evidence for a strong association between consumption of potentially contaminated food and DTC risk.


Subject(s)
Chernobyl Nuclear Accident , Diet/adverse effects , Feeding Behavior , Food Contamination, Radioactive/analysis , Neoplasms, Radiation-Induced/etiology , Radioactive Fallout/adverse effects , Thyroid Neoplasms/etiology , Adenocarcinoma, Follicular/epidemiology , Adenocarcinoma, Follicular/etiology , Adolescent , Adult , Carcinoma, Papillary/epidemiology , Carcinoma, Papillary/etiology , Case-Control Studies , Child , Child, Preschool , Female , France/epidemiology , Humans , Infant , Infant, Newborn , Neoplasms, Radiation-Induced/epidemiology , Risk Factors , Thyroid Neoplasms/epidemiology , Young Adult
6.
Eur Thyroid J ; 5(2): 132-8, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27493888

ABSTRACT

PURPOSE: Physical activity has been hypothesized to influence cancer occurrence through several mechanisms. To date, its relation with thyroid cancer risk has been examined in relatively few studies. We pooled 2 case-control studies conducted in Cuba and Eastern France to assess the relationship between self-reported practice of recreational physical activity since childhood and thyroid cancer risk. METHODS: This pooled study included 1,008 cases of differentiated thyroid cancer (DTC) matched with 1,088 controls (age range 9-35 and 17-60 years in the French and Cuban studies, respectively). Risk factors associated with the practice of recreational physical activity were estimated using OR and 95% CI. Logistic regressions were stratified by age class, country, and gender and were adjusted for ethnic group, level of education, number of pregnancies for women, height, BMI, and smoking status. RESULTS: Overall, the risk of thyroid cancer was slightly reduced among subjects who reported recreational physical activity (OR = 0.8; 95% CI 0.5-1.0). The weekly frequency (i.e. h/week) seems to be more relevant than the duration (years). CONCLUSION: Long-term recreational physical activity, practiced since childhood, may reduce the DTC risk. However, the mechanisms whereby the DTC risk decreases are not yet entirely clear.

7.
Am J Epidemiol ; 182(3): 202-14, 2015 Aug 01.
Article in English | MEDLINE | ID: mdl-26133374

ABSTRACT

The incidence of thyroid cancer has risen over the past decade, along with a rise in obesity. We studied the role of anthropometric risk factors for differentiated thyroid cancer at the time of diagnosis and at age 20 years in a case-control study conducted in eastern France between 2005 and 2010. The study included 761 adults diagnosed with differentiated thyroid cancer before 35 years of age between 2002 and 2006. They were matched with 825 controls from the general population. Odds ratios were calculated using conditional logistic regression models and were reported for all participants, those with papillary cancer only, and women only. The risk of thyroid cancer was higher for participants with a high body surface area (BSA), great height, or excess weight and for women with a high body fat percentage. Conversely, no significant association was found between body mass index and the risk of thyroid cancer. In the present study, we provide further evidence of the role of BSA and excess weight in the risk of thyroid cancer. These epidemiologic observations should be confirmed by further exploration of the biological mechanisms responsible for the associations of obesity and BSA with thyroid cancer.


Subject(s)
Adenocarcinoma, Papillary/epidemiology , Obesity/epidemiology , Thyroid Neoplasms/epidemiology , Adenocarcinoma, Papillary/pathology , Adolescent , Adult , Age Distribution , Anthropometry , Body Mass Index , Case-Control Studies , Cell Differentiation , Comorbidity , Female , France/epidemiology , Humans , Incidence , Male , Multivariate Analysis , Odds Ratio , Risk Factors , Sex Distribution , Thyroid Neoplasms/pathology , Young Adult
8.
Rev Prat ; 65(1): 93-4, 96-8, 2015 Jan.
Article in French | MEDLINE | ID: mdl-25842445

ABSTRACT

Three major nuclear events, the Hirosima and Nagasaki bombings and the Chernobyl and Fukushima catastrophes, have been selected to Illustrate the health consequences, observed or anticipated, of irradation of populations. Differences in doses and modalities of irradiation, with the combination of clinical epidemiology and dose estimates, recently revisited, allow for more accurate dose-effect relationship models of the risks. However, extrapolation to the low-doses (< 0.1 Gy) or very low-doses of these models obtained with doses ≥ 0.2 Gy remains hazardous.


Subject(s)
Radiation Injuries/etiology , Radioactive Hazard Release , Chernobyl Nuclear Accident , Fukushima Nuclear Accident , History, 20th Century , History, 21st Century , Humans , Japan/epidemiology , Neoplasms, Radiation-Induced/epidemiology , Nuclear Warfare , Public Health , Radiation Injuries/epidemiology , Radiation Injuries/history , Radioactive Hazard Release/statistics & numerical data
10.
Am J Epidemiol ; 180(10): 1007-17, 2014 Nov 15.
Article in English | MEDLINE | ID: mdl-25269571

ABSTRACT

The incidence of thyroid cancer has increased in eastern Europe since the Chernobyl nuclear power plant accident. Although the radioactive fallout was much less severe and the thyroid radiation dose was much lower in France, a case-control study was initiated in eastern France. The present study included 633 young women who were diagnosed with differentiated thyroid cancer before 35 years of age between 2002 and 2006 and matched with 677 controls. Face-to-face interviews were conducted from 2005 to 2010. Odds ratios were calculated using conditional logistic regressions and were reported in the total group and by histopathological type of cancer ("only papillary" and "excluding microcarcinomas"). The risk of thyroid cancer was higher in women who had a higher number of pregnancies, used a lactation suppressant, or had early menarche. Conversely, breastfeeding, oral contraceptive use, and late age at first pregnancy were associated with a lower risk of thyroid cancer. No association was observed between thyroid cancer and having irregular menstrual cycle, undergoing treatment for menstrual cycle regularity shortly after menarche, having a cessation of menstruation, use of another contraceptive, history of miscarriage or abortion for the first pregnancy, or having had gestational diabetes. This study confirms the role of hormonal and reproductive factors in thyroid cancer, and our results support the fact that exposure to estrogens increases thyroid cancer risk.


Subject(s)
Carcinoma, Papillary/epidemiology , Carcinoma/epidemiology , Environmental Exposure/adverse effects , Estrogens/adverse effects , Menarche , Reproductive History , Thyroid Neoplasms/epidemiology , Adult , Carcinoma/etiology , Carcinoma, Papillary/etiology , Case-Control Studies , Female , France/epidemiology , Humans , Incidence , Pregnancy , Risk Factors , Thyroid Cancer, Papillary , Thyroid Neoplasms/etiology
11.
Eur J Endocrinol ; 171(4): 451-60, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25214232

ABSTRACT

CONTEXT: Hyperthyroidism occurs in 1% of neonates born to mothers with active or past Graves' disease (GD). Current guidelines for the management of GD during pregnancy were based on studies conducted with first-generation thyroid-binding inhibitory immunoglobulin (TBII) assays. OBJECTIVE: This retrospective study was conducted in order to specify the second-generation TBII threshold predictive of fetal and neonatal hyperthyroidism, and to identify other factors that may be helpful in predicting neonatal hyperthyroidism. METHODS: We included 47 neonates born in the Lyon area to 42 mothers harboring measurable levels of TBII during pregnancy. TBII measurements were carried out in all mothers; bioassays were carried out in 20 cases. RESULTS: Nine neonates were born with hyperthyroidism, including five with severe hyperthyroidism requiring treatment. Three neonates were born with hypothyroidism. All hyperthyroid neonates were born to mothers with TBII levels >5 IU/l in the second trimester (sensitivity, 100% and specificity, 43%). No mother with TSH receptor-stimulating antibodies (TSAb measured by bioassay) below 400% gave birth to a hyperthyroid neonate. Among mothers of hyperthyroid neonates, who required antithyroid drugs during pregnancy, none could stop treatment before delivery. Analysis of TBII evolution showed six unexpected cases of increasing TBII values during pregnancy. CONCLUSION: Maternal TBII value over 5 IU/l indicates a risk of neonatal hyperthyroidism. Among these mothers, a TSAb measurement contributes to identify more specifically those who require a close fetal thyroid ultrasound follow-up. These results should be confirmed in a larger series.


Subject(s)
Graves Disease/immunology , Immunoglobulins, Thyroid-Stimulating/blood , Infant, Newborn, Diseases/immunology , Pregnancy Complications/immunology , Prenatal Exposure Delayed Effects/immunology , Thyroid Gland/immunology , Adult , Biomarkers/blood , Female , France , Humans , Infant, Newborn , Male , Predictive Value of Tests , Pregnancy , Retrospective Studies
12.
Rev Prat ; 64(6): 822-4, 2014 Jun.
Article in French | MEDLINE | ID: mdl-25090769

ABSTRACT

Autoimmune thyroid diseases (AITD) are generally of low severity although they can affect significantly the quality of life. Nevertheless, taking into account their high prevalence, a source of considerable medical expenses, it is mandatory that practitioners are well informed on the management of AITD so that they might contribute to curb as much as possible the current costs. Main points discussed are the various clinical and pathophysiological presentations of AITD, as well as their epidemiology and susceptibility/triggering factors. This overview together with the other contributions within this issue should help doctors in the diagnosis and management of AITD.


Subject(s)
Thyroid Diseases/immunology , Autoimmune Diseases/diagnosis , Autoimmune Diseases/etiology , Genetic Predisposition to Disease , Humans , Risk Factors , Thyroid Diseases/diagnosis
15.
Eur J Endocrinol ; 170(6): R253-62, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24616413

ABSTRACT

Bexarotene (Targretin), approved since 1999 as a second-line treatment for late stage cutaneous T-cell lymphomas, has been shown to induce significant hypothyroidism through TSH suppression. This review revisits, through a case report, mechanisms by which rexinoids repress the expression of TSHB gene as well as αTSH and TRH genes. It appears that rexinoids suppress TSH independently from tri-iodothyronine. Bexarotene also differently affects the gene expression of deiodinases 1 and 2 as well as the peripheral clearance of thyroxine. These data might open new ways of research on the potential interaction between thyroid axis and endogenous rexinoids.


Subject(s)
Antineoplastic Agents/adverse effects , Endocrine System Diseases/chemically induced , Lymphoma, T-Cell, Cutaneous/drug therapy , Retinoids/metabolism , Skin Neoplasms/drug therapy , Tetrahydronaphthalenes/adverse effects , Thyroid Gland/drug effects , Aged , Bexarotene , Female , Gene Expression/drug effects , Humans , Mycosis Fungoides/drug therapy , Tetrahydronaphthalenes/therapeutic use , Thyroid Gland/physiology , Thyrotropin/metabolism , Thyrotropin, beta Subunit/genetics
16.
Bull Acad Natl Med ; 197(1): 43-59; discussion 60-3, 2013 Jan.
Article in French | MEDLINE | ID: mdl-24672979

ABSTRACT

This review of human autoimmune thyroid disease (AITD) focuses mainly on the epidemiology and pathophysiology of this very common disorder, although some specific clinical situations are discussed. One peculiarity of AITD is the existence of two contrasting phenotypes: hypothyroid thyroiditis and hyperthyroid Graves' disease. Graves' disease is characterized by the presence of anti-TSH receptor antibodies capable of activating the TSH receptor, leading to thyroid hypertrophy and hyperfunction. In contrast, autoimmune thyroiditis progresses slowly, through necrosis/apoptosis of thyroid cells and their functional impairment. Other forms of autoimmune thyroiditis such as postpartum thyroiditis and silent thyroiditis are also described. The aim of this non exhaustive review is to provide the interested reader with basic information required for further investigation.


Subject(s)
Thyroiditis, Autoimmune , Autoantibodies/immunology , Autoimmunity/physiology , Environment , Genetic Predisposition to Disease , Humans , Immunoglobulins, Thyroid-Stimulating/physiology , Receptors, Thyrotropin/immunology , Thyroid Gland/immunology , Thyroiditis, Autoimmune/epidemiology , Thyroiditis, Autoimmune/etiology , Thyroiditis, Autoimmune/immunology
17.
Presse Med ; 41(12 P 2): e611-25, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23164679

ABSTRACT

This overview of the thyroid autoimmunity in human presents the various facets of a very common pathology. Focus is rather on fundamental than clinical aspects, although some specific clinical situations are discussed. Epidemiology, pathophysiology and pathology of AITD are detailed. One of the peculiarities of AITD is that they express two opposed phenotypes, hypothyroid thyroiditis and hyperthyroid Graves' disease. The latter is characterised by the presence of a unique type of autoantibodies, the anti-TSH receptor antibodies. Those are capable to activate the TSH receptor leading to the gland hypertrophy and hyperfunction. On the contrary, the autoimmune thyroiditis processus progressively and slowly tends to the necrosis/apoptosis of thyroid cells and their functional impairment. Other forms of autoimmune thyroiditis, postpartum thyroiditis and silent thyroiditis are also described. This review, which is not exhaustive, aims at providing a wide scope on the AITD, a basis from which the interested reader or the specialist will be able to find routes towards deeper knowledge.


Subject(s)
Thyroiditis, Autoimmune , Autoantibodies/immunology , Autoimmunity/immunology , Disease Susceptibility , Humans , Models, Biological , Risk Factors , Thyroid Gland/immunology , Thyroiditis, Autoimmune/epidemiology , Thyroiditis, Autoimmune/etiology , Thyroiditis, Autoimmune/pathology , Thyroiditis, Autoimmune/therapy
18.
Thyroid ; 22(5): 522-8, 2012 May.
Article in English | MEDLINE | ID: mdl-22468941

ABSTRACT

BACKGROUND: Iodine deficiency (ID) remains common in Europe, and may be especially detrimental during pregnancy. The aim of our study was to assess iodine status and thyroid function in healthy pregnant women in the Lyon metropolitan area. METHODS: In a cross-sectional study, healthy pregnant women (n=228) with no history of thyroid disease were consecutively recruited from an obstetric clinic during all trimesters. Thyrotropin (TSH), free thyroxine (FT4), anti-thyroid peroxidase (anti-TPO) antibodies, thyroglobulin (Tg), and urinary iodine concentration (UIC) (n=100) were measured. Thyroid functions were compared with those in a control group of nonpregnant adults. RESULTS: The median (range) UIC was 81 (8-832) µg/L, and 77% of pregnant women had a UIC <150 µg/L, indicating inadequate iodine intake. Overall, 11% of women had abnormal TSH or anti-TPO. The median FT4 (pmol/L) was 14.9, 12.6, and 11.5 in the first, second, and third trimesters, respectively. The median Tg in pregnant women was 16.2 µg/L, did not differ across trimesters, and was significantly higher than in the control group of nonpregnant adults (11.7 µg/L) (p=0.02). Controlling for maternal age and week of gestation, UIC was not a significant predictor of any of the thyroid function tests. CONCLUSIONS: Pregnant women in the Lyon area are iodine deficient and have increased serum Tg concentrations compared with nonpregnant controls, likely due to physiological thyroid hyperstimulation during gestation exacerbated by ID.


Subject(s)
Iodine/deficiency , Pregnancy Complications/blood , Thyroglobulin/blood , Adolescent , Adult , Cross-Sectional Studies , Female , France , Humans , Iodide Peroxidase/blood , Iodine/chemistry , Male , Middle Aged , Obstetrics/methods , Pregnancy , Reference Values , Thyrotropin/blood , Thyroxine/blood , Treatment Outcome
19.
Eur J Endocrinol ; 166(2): 247-53, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22058081

ABSTRACT

OBJECTIVE: The objective of this study was to investigate the side effects of glucocorticoid (GC) therapy observed by European thyroidologists during the treatment of Graves' orbitopathy (GO). DESIGN: A questionnaire-based survey among members of the European Thyroid Association (ETA) who treat GO. RESULTS: A response was obtained from 128 ETA members of which 115 used GC therapy for GO. The majority of respondents (83/115, 72%) used intravenous (i.v.) GC, with a relatively wide variety of therapeutic regimens. The cumulative dose of methylprednisolone ranged between 0.5 and 12 g (median 4.5 g) for i.v.GC and between 1.0 and 4.9 g (median 2.4 g) for oral GC. Adverse events were often reported during oral GCs (26/32, 81%); most side effects were non-severe, but ten respondents reported severe adverse events (hepatic, cardiovascular, and cerebrovascular complications), including two fatal cases, both receiving a total of 2.3 g prednisone. Adverse events were less common in i.v.GC (32/83 respondents, 39%), but mostly consisted of severe events, including seven fatal cases. All but one fatal event occurred in cumulative i.v.GC doses (>8 g) higher than those currently recommended. CONCLUSIONS: GCs are preferentially administered i.v. for the treatment of GO in Europe. Both oral and i.v.GC may be associated with severe adverse effects, including fatal cases, which are more frequently reported in daily or alternate day i.v.GC. IvGC therapy should be undertaken in centers with appropriate expertise. Patients should be carefully examined for risk factors before treatment and monitored for side effects, which may be asymptomatic, both during and after treatment.


Subject(s)
Drug-Related Side Effects and Adverse Reactions/epidemiology , Drug-Related Side Effects and Adverse Reactions/mortality , Glucocorticoids/adverse effects , Glucocorticoids/therapeutic use , Graves Ophthalmopathy/drug therapy , Adult , Adverse Drug Reaction Reporting Systems/statistics & numerical data , Aged , Committee Membership , Data Collection , Dose-Response Relationship, Drug , Drug Administration Routes , Drug Administration Schedule , Endocrinology/organization & administration , Europe/epidemiology , Female , Glucocorticoids/administration & dosage , Graves Ophthalmopathy/epidemiology , Graves Ophthalmopathy/mortality , Humans , Male , Methylprednisolone/administration & dosage , Methylprednisolone/adverse effects , Methylprednisolone/therapeutic use , Middle Aged , Practice Patterns, Physicians'/statistics & numerical data , Societies, Medical/organization & administration , Surveys and Questionnaires , Thyroid Gland , Young Adult
20.
Presse Med ; 40(12 Pt 1): 1155-62, 2011 Dec.
Article in French | MEDLINE | ID: mdl-22078090

ABSTRACT

One of the more prevalent among the organ-specific autoimmune diseases, Graves' disease share their chronic evolution and lack of immunomodulatory treatment. Treatment strategy has to consider as opposite options as medical conservatory or ablative approach which requires much expertise and attention to patients' wish. Whatever treatment option, it is mandatory to prevent any risk of iatrogenic hypothyroidism, especially a rise of TSH above normal limit. The long-lasting benefit-risk ratio of treatment options is of primordial importance in this usually benign but enduring disease. Occurrence of Graves' orbitopathy, a significant complication, requires a special multidisciplinary management; the same is true in the case of a current or planned pregnancy. Overall quality-of-life is often markedly affected by Graves' disease; this should not be overlooked. Smoking increases relapse risk after a course of antithyroid drug; it also increases the risk and severity of Graves' orbitopathy. Patients must be made aware of these deleterious effects and encouraged to quit smoking.


Subject(s)
Graves Disease/therapy , Adrenergic beta-Antagonists/therapeutic use , Antithyroid Agents/therapeutic use , Choice Behavior , Contraindications , Decision Making , Dissent and Disputes , Endocrinology/methods , Endocrinology/trends , Female , Graves Disease/complications , Graves Disease/diagnosis , Humans , Iodine/therapeutic use , Iodine Radioisotopes/adverse effects , Iodine Radioisotopes/therapeutic use , Pregnancy , Pregnancy Complications/diagnosis , Pregnancy Complications/therapy , Thyroidectomy/statistics & numerical data
SELECTION OF CITATIONS
SEARCH DETAIL
...